Trimer-Tag™ Oncology

With the Trimer-Tag™ technology platform, we have successfully designed and developed SCB-313 as a covalently-linked, native-like trimeric fusion protein which is structurally and functionally differentiated from the dimeric antibody-based structures and other native ligand-based candidates targeting this pathway. We are developing SCB-313 for the treatment of malignant ascites (MA), malignant pleural effusions (MPE), and peritoneal carcinomatosis (PC) to address the global unmet medical need of intracavitary malignancies.

In December 2021, we entered a partnership with Ascentage to jointly conduct Phase 1b/2 study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and efficacy of SCB-313 in combination with APG-1387 for the treatment of patients with primary or secondary peritoneal carcinomatosis.

We are also advancing SCB-219M, a novel TPO-mimetic Fc-fusion protein, being developed for the treatment of chemotherapy-induced thrombocytopenia (CIT). We initiated a Phase 1 trial in June 2022.